The Successful Use of Upadacitinib as Monotherapy for Hidradenitis Suppurativa and Ulcerative Colitis in the Setting of Refractory Disease

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2024-09-11 DOI:10.1111/pde.15759

Meryem T. Ok, Paul B. Googe, Christopher J. Sayed, Craig Burkhart, Ajay S. Gulati, Elizabeth L. Nieman

引用次数: 0

Abstract

Hidradenitis suppurativa (HS) and ulcerative colitis (UC) are associated chronic inflammatory conditions with complex disease courses and potential for overlapping therapeutic management. We describe a case of severe pediatric HS and UC that were poorly controlled despite several standard‐of‐care therapies, including infliximab and ustekinumab. Transitioning the patient to upadacitinib monotherapy resulted in clinical improvement of both her UC and HS within 3 months, and she was then able to be weaned off her other systemic therapies. While upadacitinib is not currently FDA‐approved for HS or pediatric UC, this case report shows promise for upadacitinib monotherapy for both of these complex inflammatory disorders.

查看原文本刊更多论文

奥帕他替尼作为单药疗法成功用于治疗难治性化脓性扁桃体炎和溃疡性结肠炎

化脓性扁桃体炎（HS）和溃疡性结肠炎（UC）是相关的慢性炎症，病程复杂，治疗方法有可能重叠。我们描述了一例严重的小儿化脓性结肠炎和溃疡性结肠炎患者，尽管他们接受了包括英夫利昔单抗和乌司替尼在内的多种标准疗法，但病情控制不佳。将患者转为使用达帕替尼单药治疗后，她的 UC 和 HS 在 3 个月内都得到了临床改善，随后她就可以停用其他系统疗法了。虽然目前达帕替尼尚未获得 FDA 批准用于治疗 HS 或儿科 UC，但这一病例报告显示了达帕替尼单药治疗这两种复杂炎症性疾病的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.